IMR Press / EJGO / Volume 42 / Issue 2 / DOI: 10.31083/j.ejgo.2021.02.5198
Open Access Review
Malignant struma ovarii: a case report and literature review
Show Less
1 Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, 100038 Beijing, China
2 Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, 100038 Beijing, China
Eur. J. Gynaecol. Oncol. 2021 , 42(2), 244–249;
Submitted: 25 February 2019 | Accepted: 30 October 2019 | Published: 15 April 2021

Background: Struma ovarii accounts for 0.2–1.3% of all ovarian tumors and 2–4% of all teratomas. There is no guideline or international consensus for malignant struma ovarii treatment so far. Case presentation: We report a case of a 42-year-old woman who was diagnosed with malignant struma ovarii 18 years prior and remains alive. The patient presented with uncommon features of primary malignant struma ovarii, locoregional recurrence and metastases and received radical treatments including cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and transcatheter arterial chemoembolization (TACE). Conclusions: We report a typical case of malignant struma ovarii successfully treated by radical comprehensive treatment, with CRS + HIPEC as the core procedure. At present, the patient remains in good condition, surviving for 18 years since the tumor was found. This case provides evidence that CRS + HIPEC may be a promising strategy to improve outcomes for struma ovarii patients.

Struma ovarii
Liver metastases
Total thyroidectomy
131I treatment
Cytoreductive surgery
Hyperthermic intraperitoneal chemotherapy
Fig. 1.
Back to top